BioDelivery Sciences International named Charles J. Bramlage and Barry I. Feinberg, MD, to the board of directors.
Dr. Feinberg is a pain management specialist and has served as the Board of Directors and Medical Executive Committee of the Frontenac Surgery and Spine Center in St. Louis since 2008. He has also been a member of the anesthesia department at Missouri Baptist Medical Center in St. Louis and an associate staff member of the anesthesia department at DePaul Health Center in Bridgeton, Mo.
Mr. Bramlage is a pharmaceutical industry executive veteran with experience in marketing, sales and other commercial functions. He is currently the CEO of Pearl Therapeutics, which was recently acquired by AstraZeneca.
BioDelivery Sciences plans to launch the company's first product, BUNAVAIL, for treating opioid independence in the near future.
More Articles on Orthopedic Devices:
15 Spine Devices Receive FDA 510(k) Clearance in June
Titan Spine Receives Research Award From Scoliosis Research Society
Cayenne Medical Launches SureLock All-Suture Anchor System